Clinical trial · no report yet · Phase 3
A-Brave
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
- NCT02926196 ↗
- Completed
- Istituto Oncologico Veneto IRCCS
- 67 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 40 | |
| YouTube | 17 | |
| Podcasts | 10 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial. Sponsor: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- MSB0010718C
- Arms
- Arm Avelumab · Experimental
- Arm Observation · No intervention
- Enrollment
- 474
- Primary outcomes
- Disease free survival
- Disease free survival in PD-L1-positive patients
- Sponsor
- Istituto Oncologico Veneto IRCCS with University of Padova, Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche
- Start
- Jun 17, 2016
- Primary completion
- Jun 2024
- Results posted
- No
- Registry record
- NCT02926196 · updated Dec 12, 2025